317 related articles for article (PubMed ID: 33128812)
1. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
Kirk AD; Adams AB; Durrbach A; Ford ML; Hildeman DA; Larsen CP; Vincenti F; Wojciechowski D; Woodle ES
Am J Transplant; 2021 May; 21(5):1691-1698. PubMed ID: 33128812
[TBL] [Abstract][Full Text] [Related]
2. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
[TBL] [Abstract][Full Text] [Related]
3. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
5. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
Divard G; Aubert O; Debiais-Deschamp C; Raynaud M; Goutaudier V; Sablik M; Sayeg C; Legendre C; Obert J; Anglicheau D; Lefaucheur C; Loupy A
Clin J Am Soc Nephrol; 2024 May; 19(5):628-637. PubMed ID: 38265815
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
Ferguson R; Grinyó J; Vincenti F; Kaufman DB; Woodle ES; Marder BA; Citterio F; Marks WH; Agarwal M; Wu D; Dong Y; Garg P
Am J Transplant; 2011 Jan; 11(1):66-76. PubMed ID: 21114656
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
9. De novo belatacept in clinical vascularized composite allotransplantation.
Cendales LC; Ruch DS; Cardones AR; Potter G; Dooley J; Dore D; Orr J; Ruskin G; Song M; Chen DF; Selim MA; Kirk AD
Am J Transplant; 2018 Jul; 18(7):1804-1809. PubMed ID: 29723921
[TBL] [Abstract][Full Text] [Related]
10. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
11. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
[TBL] [Abstract][Full Text] [Related]
12. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1774-1782. PubMed ID: 29573335
[TBL] [Abstract][Full Text] [Related]
13. Experience with belatacept rescue therapy in kidney transplant recipients.
Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
[TBL] [Abstract][Full Text] [Related]
14. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive minimization with mTOR inhibitors and belatacept.
Diekmann F
Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
[TBL] [Abstract][Full Text] [Related]
17. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys.
Song L; Ma A; Dun H; Hu Y; Fujii Y; Kinugasa F; Oshima S; Higashi Y; Daloze P; Chen H
Am J Transplant; 2017 Mar; 17(3):635-645. PubMed ID: 27598231
[TBL] [Abstract][Full Text] [Related]
18. De Novo Belatacept in a Human Immunodeficiency Virus-Positive Kidney Transplant Recipient.
Cohen EA; Mulligan D; Kulkarni S; Tichy EM
Am J Transplant; 2016 Sep; 16(9):2753-7. PubMed ID: 27137752
[TBL] [Abstract][Full Text] [Related]
19. Utility of a fusion protein T-cell co-stimulation blocker Belatacept in heart transplant recipients: Real world experience from a high volume center.
Oren D; Uriel M; Moeller CM; Valledor AF; DeFilippis EM; Lotan D; Colombo PC; Yuzefpolskaya M; Topkara VK; Clerkin KJ; Raikhelkar JK; Fried JA; Oh DKT; Bae D; Lin E; Theodoropoulos K; Naka Y; Takeda K; Choe J; Jennings DL; Majure D; Latif F; Sayer G; Uriel N
Clin Transplant; 2024 Mar; 38(3):e15251. PubMed ID: 38504576
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.
Durrbach A; Pestana JM; Florman S; Del Carmen Rial M; Rostaing L; Kuypers D; Matas A; Wekerle T; Polinsky M; Meier-Kriesche HU; Munier S; Grinyó JM
Am J Transplant; 2016 Nov; 16(11):3192-3201. PubMed ID: 27130868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]